X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (58) 58
Book Chapter (7) 7
Book Review (5) 5
Dissertation (5) 5
Magazine Article (3) 3
Conference Proceeding (2) 2
Report (2) 2
Web Resource (2) 2
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (29) 29
humans (20) 20
animals (11) 11
male (10) 10
abridged index medicus (9) 9
female (9) 9
hematology (9) 9
middle aged (9) 9
aged (7) 7
biochemistry & molecular biology (6) 6
kinetics (6) 6
research (6) 6
smooth-muscle cells (6) 6
cells, cultured (5) 5
substrate specificity (5) 5
volcanoes (5) 5
adult (4) 4
endothelial-cells (4) 4
endothelium, vascular - cytology (4) 4
endothelium, vascular - metabolism (4) 4
physiological aspects (4) 4
structure-activity relationship (4) 4
transforming growth factor beta - chemistry (4) 4
amino acid sequence (3) 3
antibodies - pharmacology (3) 3
atherosclerosis (3) 3
biochemical research methods (3) 3
biotechnology & applied microbiology (3) 3
bovine endothelial-cells (3) 3
chemokine ccl1 (3) 3
chemotherapy (3) 3
coronary artery disease - metabolism (3) 3
dose-response relationship, drug (3) 3
endothelium (3) 3
fatty acids (3) 3
glucose (3) 3
growth-factor-beta (3) 3
immunohistochemistry (3) 3
inflammation (3) 3
metabolism (3) 3
molecular sequence data (3) 3
molecular-cloning (3) 3
mutagenesis, site-directed (3) 3
oncology (3) 3
peptides (3) 3
rats (3) 3
receptors, ccr8 (3) 3
stem cells (3) 3
therapy (3) 3
transforming growth factor beta - metabolism (3) 3
transplantation (3) 3
trial (3) 3
acetyl-coa carboxylase (2) 2
activation (2) 2
aged, 80 and over (2) 2
angina pectoris - complications (2) 2
angina pectoris - metabolism (2) 2
angina, unstable - metabolism (2) 2
angioplasty, balloon, coronary (2) 2
antarctica (2) 2
antineoplastic agents - adverse effects (2) 2
binding sites (2) 2
binding-protein (2) 2
biology (2) 2
bryophytes (2) 2
canada (2) 2
cancer (2) 2
carbohydrates (2) 2
cardiac & cardiovascular systems (2) 2
cardiomyopathy (2) 2
cardiotonic agents - pharmacology (2) 2
carrier proteins - metabolism (2) 2
cellular biology (2) 2
chemokines, cc - metabolism (2) 2
chemokines, cc - pharmacology (2) 2
chemotactic factors - pharmacology (2) 2
chemotaxis - drug effects (2) 2
clarithromycin - administration & dosage (2) 2
cocultures (2) 2
conscious dogs (2) 2
coronary artery disease - complications (2) 2
coronary artery disease - therapy (2) 2
coronary vessels (2) 2
coronary vessels - metabolism (2) 2
culture media, conditioned - pharmacology (2) 2
cyclic amp - metabolism (2) 2
dexamethasone - administration & dosage (2) 2
dextrose (2) 2
dilated cardiomyopathy (2) 2
dioxygenases (2) 2
electron spin resonance spectroscopy (2) 2
endothelial cells (2) 2
endothelial lipase (2) 2
energy metabolism - drug effects (2) 2
entomology (2) 2
enzyme inhibitors (2) 2
eruptive history (2) 2
escherichia-coli (2) 2
extracellular-matrix (2) 2
follow-up studies (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 06/2015, Volume 10, Issue 6, pp. e0130894 - e0130894
Previous studies have shown that glucagon-like peptide-1 (GLP-1) provides cardiovascular benefits independent of its role on peripheral glycemic control.... 
CONSCIOUS DOGS | PROLONGS SURVIVAL | GLYCEMIC CONTROL | MULTIDISCIPLINARY SCIENCES | VENTRICULAR SYSTOLIC FUNCTION | IN-VIVO | FAILURE-PRONE RAT | INTRAMUSCULAR GLUCOSE-METABOLISM | DILATED CARDIOMYOPATHY | INDIVIDUAL TISSUES | MYOCARDIAL ISCHEMIA/REPERFUSION INJURY | Glucagon-Like Peptide 1 - administration & dosage | Magnetic Resonance Spectroscopy | Glucagon-Like Peptide 1 - pharmacology | Rats | Carbon Isotopes - metabolism | Cardiotonic Agents - pharmacology | Oxygen Consumption - physiology | Animals | Cardiotonic Agents - administration & dosage | Myocardium - metabolism | Glucose - metabolism | Myocytes, Cardiac - metabolism | Energy Metabolism - physiology | Cyclic AMP - metabolism | Fatty Acids - metabolism | Reperfusion Injury - metabolism | Energy Metabolism - drug effects | Hydrogen-Ion Concentration | Lactates | Glucose metabolism | Energy use | Glucagon | Ischemia | Glycogen | Physiological aspects | Energy efficiency | Glucose | Fatty acids | Dextrose | Diabetes therapy | Heart | Nuclear magnetic resonance--NMR | Peptides | Cardiomyopathy | Homeostasis | Myocardial ischemia | Kinases | Palmitic acid | Reperfusion | Rodents | Oxidation | Heart diseases | Glucagon-like peptide 1 | Heart failure | Carbohydrates | Contractility | Cyclic AMP | Cardiomyocytes | Metabolism | Insulin | Muscle contraction | Substrates | Switching | Medical prognosis | Coronary vessels | Remote regions | Glycolysis | Lactic acid | Laboratory animals | Oxygenation | Veins & arteries | Index Medicus | Nuclear magnetic resonance | NMR
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2011, Volume 6, Issue 8, pp. e23570 - e23570
Background: The cardioprotective effects of glucagon-like peptide-1 (GLP-1) and analogs have been previously reported. We tested the hypothesis that... 
INFARCT SIZE | CONSCIOUS DOGS | MYOCARDIAL-INFARCTION | BIOLOGY | REPERFUSION | RECEPTOR | INTRAMUSCULAR GLUCOSE-METABOLISM | DILATED CARDIOMYOPATHY | LEFT-VENTRICULAR PERFORMANCE | INDIVIDUAL TISSUES | FAILURE | Heart | Transcription, Genetic - drug effects | Glucagon-Like Peptide 1 - administration & dosage | Lactic Acid - blood | Myocardial Reperfusion Injury - complications | Body Weight - drug effects | Glucagon-Like Peptide 1 - blood | Male | Insulin - blood | Myocardial Infarction - pathology | Myocardium - metabolism | Myocardial Infarction - physiopathology | Cyclic AMP - metabolism | Heart Function Tests | Principal Component Analysis | Glucagon-Like Peptide 1 - analogs & derivatives | Glucagon-Like Peptide 1 - pharmacology | Rats | Cardiotonic Agents - pharmacology | Rats, Sprague-Dawley | Myocardial Reperfusion Injury - physiopathology | Feeding Behavior - drug effects | Myocardial Infarction - complications | Metabolic Networks and Pathways - genetics | Animals | Hemodynamics - drug effects | Metabolic Networks and Pathways - drug effects | Blood Glucose - metabolism | In Vitro Techniques | Energy Metabolism - drug effects | Myocardial Reperfusion Injury - prevention & control | Type 2 diabetes | Glucose metabolism | Glucagon | Ischemia | Genes | Physiological aspects | Amino acids | Carbohydrate metabolism | Glucose | Gene expression | Dextrose | Myocardial infarction | Peptides | Cardiomyopathy | Myocardial ischemia | Cardiovascular disease | Reperfusion | Rodents | Spectrum analysis | Oxidation | Heart diseases | Glucagon-like peptide 1 | Injuries | Heart failure | Hypertension | Efflux | Carbohydrates | Radioactive half-life | Metabolism | Fatty acids | Substrates | Studies | Coronary vessels | Myocardium | Hemodynamics | Ventricle | Diabetes | Lactic acid | Laboratory animals | Index Medicus
Journal Article
Clinical orthopaedics and related research, ISSN 0009-921X, 10/1995, Issue 319, pp. 16 - 27
Journal Article
Blood, ISSN 0006-4971, 2008, Volume 111, Issue 3, pp. 1101 - 1109
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2008, Volume 14, Issue 7, pp. 795 - 798
Journal Article
Molecular Biology of the Cell, ISSN 1059-1524, 1998, Volume 9, Issue 9, pp. 2627 - 2638
The multipotential cytokine transforming growth factor-β (TGF-β) is secreted in a latent form. Latency results from the noncovalent association of TGF-β with... 
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 12/1998, Volume 32, Issue 7, pp. 2035 - 2042
Journal Article
Blood, ISSN 0006-4971, 02/2004, Volume 103, Issue 4, pp. 1296 - 1304
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 5/2008, Volume 16, Issue 5, pp. 477 - 483
Journal Article
The Journal of Cell Biology, ISSN 0021-9525, 2/1993, Volume 120, Issue 4, pp. 995 - 1002
Transforming growth factor beta (TGF-β) is released from cells in a latent form consisting of the mature growth factor associated with an aminoterminal... 
Cell growth | Coculture techniques | Antibodies | Granulosa cells | Cultured cells | Transforming growth factors | Human growth | Platelets | Endothelial cells | Cells | Smooth muscle | Research | Carrier proteins | Endothelium | Index Medicus
Journal Article
Journal of Biomolecular Screening, ISSN 1087-0571, 07/2008, Volume 13, Issue 6, pp. 468 - 475
Journal Article
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2006, Volume 12, Issue 8, pp. 868 - 875
Nonmyeloablative transplantation (NMT) is intended to be less toxic than traditional allografts, but such regimens as fludarabine/melphalan still pose a... 
Reduced intensity transplantation | Graft-vs-host disease | Hematological malignancies | Campath | hematological malignancies | SURVIVAL | ALEMTUZUMAB | CD52 | graft-vs-host disease | BONE-MARROW-TRANSPLANTATION | IMMUNOLOGY | TRANSPLANTATION | reduced intensity transplantation | THERAPY | campath | LEUKEMIA | MONOCLONAL-ANTIBODIES | HEMATOLOGY | Hematologic Neoplasms - therapy | Follow-Up Studies | Myeloablative Agonists - adverse effects | Hematologic Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Living Donors | Antineoplastic Agents - administration & dosage | Transplantation Conditioning - mortality | Transplantation, Homologous | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Graft vs Host Disease - mortality | Melphalan - adverse effects | Antineoplastic Agents - adverse effects | Adult | Female | Hematologic Neoplasms - complications | Stem Cell Transplantation - mortality | Transplantation Conditioning - methods | Graft vs Host Disease - etiology | Vidarabine - adverse effects | Survival Rate | Graft vs Host Disease - blood | Vidarabine - analogs & derivatives | Alemtuzumab | Antibodies, Neoplasm - administration & dosage | Disease-Free Survival | Whole-Body Irradiation - methods | Melphalan - administration & dosage | Stem Cell Transplantation - methods | Hematologic Neoplasms - blood | Antibodies, Monoclonal - administration & dosage | Graft Survival - radiation effects | Myeloablative Agonists - administration & dosage | Graft vs Host Disease - prevention & control | Aged | Vidarabine - administration & dosage | Graft Survival - drug effects | Antibodies, Neoplasm - adverse effects | Medical research | Care and treatment | Fluconazole | Cardiac patients | Stem cells | Medicine, Experimental | Transplantation | Acyclovir | Cancer | Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 2000, Volume 102, Issue 7, pp. 786 - 792
Journal Article